Literature DB >> 32111534

European Society for Sexual Medicine Position Statement "Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction".

Guy T'Sjoen1, Jon Arcelus2, Annelou L C De Vries3, Alessandra D Fisher4, Timo O Nieder5, Müjde Özer6, Joz Motmans7.   

Abstract

BACKGROUND: There is a general lack of recommendations for and basic information tailored at sexologists and other health-care professionals for when they encounter trans people in their practice. AIM: We present to clinicians an up-to-date overview of clinical consensus statements on trans health care with attention for sexual function and satisfaction.
METHODS: The task force consisted of 7 clinicians experienced in trans health care, selected among European Society for Sexual Medicine (ESSM) scientific committee. The consensus was guided by clinical experience and a review of the available literature and by interactive discussions on trans health, with attention for sexual function and satisfaction where available. OUTCOMES: The foci of the study are assessment and hormonal aspects of trans health care.
RESULTS: As the available literature for direct recommendations was limited, most of the literature was used as background or indirect evidence. Clinical consensus statements were developed based on clinical experiences and the available literature. With the multiple barriers to care that many trans people experience, basic care principles still need to be stressed. We recommend that health-care professionals (HCPs) working with trans people recognize the diversity of genders, including male, female, and nonbinary individuals. In addition, HCPs assessing gender diverse children and adolescents should take a developmental approach that acknowledges the difference between prepubescent gender diverse children and pubescent gender diverse adolescents and trans adults. Furthermore, trans people seeking gender-affirming medical interventions should be assessed by HCPs with expertise in trans health care and gender-affirming psychological practice. If masculinization is desired, testosterone therapy with monitoring of serum sex steroid levels and signs of virilization is recommended. Similarly, if feminization is desired, we recommend estrogens and/or antiandrogen therapy with monitoring of serum sex steroid levels and signs of feminization. HCPs should be aware of the influence of hormonal therapy on sexual functioning and satisfaction. We recommend HCPs be aware of potential sexual problems during all surgical phases of treatment. CLINICAL IMPLICATIONS: This is an up-to-date ESSM position statement. STRENGTHS & LIMITATIONS: These statements are based on the data that are currently available; however, it is vital to recognize that this is a rapidly changing field and that the literature, particularly in the field of sexual functioning and satisfaction, is limited.
CONCLUSION: This ESSM position statement provides relevant information and references to existing clinical guidelines with the aim of informing relevant HCPs on best practices when working with transgender people. T'Sjoen G, Arcelus J, De Vries ALC, et al. European Society for Sexual Medicine Position Statement "Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction". J Sex Med 2020;XX:XXX-XXX.
Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Feminization; Gender Diverse; Gender Incongruence; Gender-Affirming Surgery; Masculinization; Nonbinary; Sexual Functioning; Sexual Satisfaction; Transgender

Year:  2020        PMID: 32111534     DOI: 10.1016/j.jsxm.2020.01.012

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  14 in total

Review 1.  Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians.

Authors:  Carlotta Cocchetti; Jiska Ristori; Francesca Mazzoli; Linda Vignozzi; Mario Maggi; Alessandra Daphne Fisher
Journal:  Int J Impot Res       Date:  2021-02-08       Impact factor: 2.896

2.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

3.  Bell v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274: Weighing current knowledge and uncertainties in decisions about gender-related treatment for transgender adolescents.

Authors:  Annelou L C de Vries; Christina Richards; Amy C Tishelman; Joz Motmans; Sabine E Hannema; Jamison Green; Stephen M Rosenthal
Journal:  Int J Transgend Health       Date:  2021-04-05

4.  International clinical practice guidelines for gender minority/trans people: systematic review and quality assessment.

Authors:  Sara Dahlen; Dean Connolly; Isra Arif; Muhammad Hyder Junejo; Susan Bewley; Catherine Meads
Journal:  BMJ Open       Date:  2021-04-29       Impact factor: 2.692

Review 5.  Rodent Model of Gender-Affirming Hormone Therapies as Specific Tool for Identifying Susceptibility and Vulnerability of Transgender People and Future Applications for Risk Assessment.

Authors:  Roberta Tassinari; Francesca Maranghi
Journal:  Int J Environ Res Public Health       Date:  2021-11-30       Impact factor: 3.390

Review 6.  Need for Inclusive Consideration of Transgender and Gender Diverse People in E-Health Services: A Systematic Review.

Authors:  Janis Renner; Lars Täuber; Timo O Nieder
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

7.  Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals.

Authors:  Johanne Andersen Hojbjerg; Astrid Ditte Højgaard; Anne-Mette Hvas
Journal:  Sex Med       Date:  2021-12-27       Impact factor: 2.491

Review 8.  Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals.

Authors:  Ada S Cheung; Hui Yin Lim; Teddy Cook; Sav Zwickl; Ariel Ginger; Cherie Chiang; Jeffrey D Zajac
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

9.  Return to work of transgender people: A systematic review through the blender of occupational health.

Authors:  Joy Van de Cauter; Hanna Van Schoorisse; Dominique Van de Velde; Joz Motmans; Lutgart Braeckman
Journal:  PLoS One       Date:  2021-11-01       Impact factor: 3.240

10.  Interdisciplinary, internet-based trans health care (i²TransHealth): study protocol for a randomised controlled trial.

Authors:  Timo O Nieder; Janis Renner; Antonia Zapf; Susanne Sehner; Amra Hot; Hans-Helmut König; Judith Dams; Thomas Grochtdreis; Peer Briken; Arne Dekker
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.